BRPI0520509A2 - antibody or epitope binding fragment, polynucleotide, host cell, and method of preparing an antibody or epitope binding fragment - Google Patents
antibody or epitope binding fragment, polynucleotide, host cell, and method of preparing an antibody or epitope binding fragmentInfo
- Publication number
- BRPI0520509A2 BRPI0520509A2 BRPI0520509-3A BRPI0520509A BRPI0520509A2 BR PI0520509 A2 BRPI0520509 A2 BR PI0520509A2 BR PI0520509 A BRPI0520509 A BR PI0520509A BR PI0520509 A2 BRPI0520509 A2 BR PI0520509A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- epitope binding
- binding fragment
- polynucleotide
- preparing
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 241001529936 Murinae Species 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ANTICORPO OU SEU FRAGMENTO DE LIGAçãO DE EPITOPO, POLINUCLEOTìDEO, CéLULA HOSPEDEIRA, E MéTODO DE PREPARAçãO DE UM ANTICORPO OU SEU FRAGMENTO DE LIGAçãO DE EPITOPO. A presente invenção refere-se a conjugados citotóxicos compreendendo um agente aglutinante de célula e um agente terapêutico, composições terapêuticas compreendendo o conjugado, métodos para o uso dos conjugados na inibição de crescimento celular e o tratamento de doença, e um kit compreendendo o conjugado citotóxico. Em particular, o agente aglutinante de célula é um anticorpo monoclonal, e seus fragmentos aglutinantes de epitopo, que reconhece e liga o glicotopo de CA6. A presente invenção também se refere a versões humanizadas e recapeadas de DS6, um anticorpo monoclonal de murino de anti-CA6, e seus fragmentos aglutinantes de epitopo.ANTIBODY OR ITS EPHYPOT CONNECTION FRAGMENT, POLYNUCLEOTIDE, HOST CELL, AND METHOD FOR PREPARING AN ANTIBODY OR ITS EPHYPOT CONNECTION FRAGMENT. The present invention relates to cytotoxic conjugates comprising a cell binding agent and a therapeutic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates to inhibit cell growth and treating disease, and a kit comprising the cytotoxic conjugate. . In particular, the cell binding agent is a monoclonal antibody, and epitope binding fragments thereof, which recognize and bind the CA6 glycotope. The present invention also relates to humanized and resurfaced versions of DS6, a murine anti-CA6 monoclonal antibody, and epitope binding fragments thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2005/030115 WO2007024222A1 (en) | 2005-08-22 | 2005-08-22 | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0520509A2 true BRPI0520509A2 (en) | 2009-05-12 |
Family
ID=37771883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0520509-3A BRPI0520509A2 (en) | 2005-08-22 | 2005-08-22 | antibody or epitope binding fragment, polynucleotide, host cell, and method of preparing an antibody or epitope binding fragment |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1917034A4 (en) |
JP (1) | JP2009504193A (en) |
CN (1) | CN101242855A (en) |
AU (1) | AU2005335743A1 (en) |
BR (1) | BRPI0520509A2 (en) |
CA (1) | CA2615761A1 (en) |
EA (1) | EA020130B9 (en) |
EC (1) | ECSP088241A (en) |
HK (1) | HK1211965A1 (en) |
IL (2) | IL189628A0 (en) |
MX (1) | MX2008002607A (en) |
NO (1) | NO20080893L (en) |
WO (1) | WO2007024222A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
CA2900154A1 (en) * | 2013-02-05 | 2014-08-14 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
US9844607B2 (en) | 2013-02-05 | 2017-12-19 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
AU2014214997A1 (en) * | 2013-02-05 | 2015-08-20 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
JP2016525560A (en) * | 2013-08-02 | 2016-08-25 | サノフイ | Use of anti-Muc1 maytansinoid immunoconjugate antibodies to treat solid tumors |
MA42561A (en) | 2014-09-02 | 2018-04-25 | Immunogen Inc | METHODS FOR FORMULATING ANTIBODY-DRUG CONJUGATE COMPOSITIONS |
PL3189056T3 (en) | 2014-09-03 | 2020-11-02 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
JP2017527562A (en) | 2014-09-03 | 2017-09-21 | イミュノジェン・インコーポレーテッド | Cytotoxic benzodiazepine derivatives |
JP2019501139A (en) | 2015-11-25 | 2019-01-17 | イミュノジェン・インコーポレーテッド | Pharmaceutical formulations and uses thereof |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
CN110366431B (en) | 2017-02-28 | 2023-07-18 | 伊缪诺金公司 | Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof |
TW201839001A (en) | 2017-04-20 | 2018-11-01 | 美商伊繆諾金公司 | Cytotoxic benzodiazepine derivatives and conjugates thereof |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
TWI827575B (en) | 2017-12-28 | 2024-01-01 | 美商伊繆諾金公司 | Benzodiazepine derivatives |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596503B1 (en) * | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
KR101424624B1 (en) * | 2003-05-14 | 2014-07-31 | 이뮤노젠 아이엔씨 | Drug Conjugate Composition |
US20050123549A1 (en) * | 2003-07-21 | 2005-06-09 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
-
2005
- 2005-08-22 EA EA200800642A patent/EA020130B9/en not_active IP Right Cessation
- 2005-08-22 CA CA002615761A patent/CA2615761A1/en not_active Abandoned
- 2005-08-22 WO PCT/US2005/030115 patent/WO2007024222A1/en active Application Filing
- 2005-08-22 JP JP2008527882A patent/JP2009504193A/en not_active Withdrawn
- 2005-08-22 MX MX2008002607A patent/MX2008002607A/en not_active Application Discontinuation
- 2005-08-22 BR BRPI0520509-3A patent/BRPI0520509A2/en not_active Application Discontinuation
- 2005-08-22 CN CNA200580051368XA patent/CN101242855A/en active Pending
- 2005-08-22 AU AU2005335743A patent/AU2005335743A1/en not_active Abandoned
- 2005-08-22 EP EP05788869A patent/EP1917034A4/en not_active Withdrawn
-
2008
- 2008-02-20 IL IL189628A patent/IL189628A0/en unknown
- 2008-02-20 NO NO20080893A patent/NO20080893L/en not_active Application Discontinuation
- 2008-03-05 EC EC2008008241A patent/ECSP088241A/en unknown
-
2015
- 2015-05-13 IL IL238798A patent/IL238798A0/en unknown
- 2015-12-31 HK HK15112923.0A patent/HK1211965A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101242855A (en) | 2008-08-13 |
EP1917034A1 (en) | 2008-05-07 |
WO2007024222A1 (en) | 2007-03-01 |
IL189628A0 (en) | 2008-06-05 |
IL238798A0 (en) | 2015-06-30 |
JP2009504193A (en) | 2009-02-05 |
CA2615761A1 (en) | 2007-03-01 |
EP1917034A4 (en) | 2009-04-29 |
ECSP088241A (en) | 2008-04-28 |
EA200800642A1 (en) | 2008-08-29 |
MX2008002607A (en) | 2008-03-19 |
AU2005335743A1 (en) | 2007-03-01 |
EA020130B9 (en) | 2014-10-30 |
EA020130B1 (en) | 2014-08-29 |
HK1211965A1 (en) | 2016-06-03 |
NO20080893L (en) | 2008-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0520509A2 (en) | antibody or epitope binding fragment, polynucleotide, host cell, and method of preparing an antibody or epitope binding fragment | |
BRPI0412879A8 (en) | CA6 ANTIGEN SPECIFIC CYTOTOXIC CONJUGATE AND METHODS OF ITS USE | |
BRPI0611414B8 (en) | antibody or antigen-binding fragment thereof that binds to human tweak, pharmaceutical composition and its uses | |
WO2008010101A3 (en) | Antagonist antibody against epha2 for the treatment of cancer | |
WO2010113117A3 (en) | Preparation of isolated agonist anti-edar monoclonal antibodies | |
CL2008002923A1 (en) | Human monoclonal antibody isolated because it binds to human mesothelin; composition comprising said antibody; conjugate between antibody and therapeutic agent; nucleic acid molecule that encodes the antibody; use to prepare a drug to treat cancer. | |
WO2008067464A3 (en) | NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES | |
RU2014124984A (en) | COMPOUNDS ANTI-MEDICINAL PRODUCT AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS | |
AU2006226733A8 (en) | Antibodies against CD38 for treatment of multiple myeloma | |
WO2010066803A3 (en) | Human antibodies against human tissue factor | |
NZ597563A (en) | Muc1 antibodies | |
NO20084650L (en) | Modified humanized anti-interleukin-18 antibodies | |
NZ593964A (en) | Human anti-alpha-synuclein autoantibodies | |
DK1446157T3 (en) | Antibodies to inhibit blood coagulation and methods for its use | |
MX2010008364A (en) | Compositions and methods for crystallizing antibody fragments. | |
BR112012013734A2 (en) | monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration. | |
WO2008136774A8 (en) | Antibodies binding to an intracellular prl-1 or prl-3 polypeptide | |
BR112021019107A2 (en) | Antibodies against amyloid-beta pyroglutamate and their uses | |
CR9823A (en) | AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME | |
WO2009120659A3 (en) | Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents | |
AU2020271352A8 (en) | Combinations of anti-ILDR2 antibodies and PD-1 antagonists | |
UA109423C2 (en) | COMPOSITION AND METHOD FOR TUMOR DIAGNOSTICS AND TREATMENT | |
MX360580B (en) | Human anti-alpha-synuclein autoantibodies. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 4A ANUIDADE. |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: IMMUNOGEN, INC. (US) Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110101858/RJ DE 30/09/2011. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: REF. A RPI NO 2166 DE 10/07/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 39/395; C12N 5/06. Ipc: C07K 16/30 (2006.01), A61K 47/68 (2017.01), C07K 1 Ipc: C07K 16/30 (2006.01), A61K 47/68 (2017.01), C07K 1 |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |